XWXirun Wan

Xirun Wan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xirun Wan has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Fengzhi Feng

    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    5 shared publications
  • Yang Xiang

    National Clinical Research Center for Women’s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    5 shared publications
  • Junjun Yang

    National Clinical Research Center for Women’s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

    4 shared publications
  • Jun Zhao

    National Clinical Research Center for Women’s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing 100730, China

    3 shared publications
  • Tong Ren

    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China

    2 shared publications
  • Changji Xiao

    Department of Obstetrics and Gynecology, Peking University First Hospital

    1 shared publication

Latest Publications

  • Open Access

    Persistent Low-Level hCG After Gestational Trophoblastic Neoplasia Remission: Treatment-Free Probability Stratified by Early hCG Course

    by Mingliang Ji, Jun Zhao, Liangyu Xia, Xirun Wan, Fengzhi Feng, Junjun Yang, Fang Jiang, Yang Xiang

    Background/Objectives: To determine treatment-free probability after persistent low-level human chorionic gonadotropin (hCG) elevation following complete remission from gestational trophoblastic neoplasia (GTN) and examine its association with the early hCG course. Methods: This single-center retrospective study included patients treated in 2015–2022 for gestational choriocarcinoma or invasive mole who developed ≥3 post-remission hCG results >5 and ≤1000 U/L over ≥14 days. The primary endpoint was retreatment for GTN recurrence. Kaplan–Meier analysis estimated treatment-free probability from the first low-level hCG elevation. Exploratory landmark analyses at 60, 90, and 180 days stratified patients still under observation by pre-landmark peak hCG (≤20 versus >20 U/L). Results: Forty-six patients contributed 595 hCG measurements. Thirty-five developed recurrence requiring retreatment; 11 remained recurrence-free. All patients whose first low-level hCG exceeded 20 U/L (n = 11) developed recurrence. Treatment-free probability was 30.4% at 1 year and 24.2% at 2 years. At the 60-, 90-, and 180-day landmarks, 365-day treatment-free probability was higher with pre-landmark peak hCG ≤ 20 U/L than >20 U/L: 68.4% versus 9.1%, 70.6% versus 22.2%, and 92.3% versus 14.3%, respectively. All 35 retreated patients achieved hCG ≤ 5 U/L after treatment. Conclusions: Most patients with persistent low-level hCG after remission from GTN developed recurrence. For patients still under observation at 60, 90, or 180 days, a peak hCG of 20 U/L or lower before the landmark was associated with higher treatment-free probability over the following year. Continued surveillance after clinical and imaging assessment is reasonable in this subgroup.

  • Open Access

    Pretreatment circulating tumor DNA and tissue genomic profiling concordance in ovarian cancer: a prospective observational study of influencing factors and clinical implications

    by Hao Su, Rong Fan, Mingle Tian, Yuan Li, Yongxue Wang, Tao Wang, Sha Wang, Xirun Wan, Fengzhi Feng

    Background: Next-generation sequencing (NGS) of plasma circulating tumor DNA (ctDNA) shows promise as a minimally invasive alternative to tissue sequencing. However, concordance between genomic alterations in tumor tissue and plasma ctDNA remains incompletely characterized in ovarian cancer, particularly in the pretreatment setting. Objectives: To identify factors influencing concordance between tissue and ctDNA genomic profiling and explore the potential clinical implications (including treatment and survival outcomes) of this concordance. Design: A prospective, single-center, observational study. Methods: A total of 40 matched pretreatment tumor specimens and blood samples were prospectively collected from patients with ovarian cancer and subsequently sequenced using a customized gene panel. Overall and individual concordance rates were calculated as the ratio of total concordant mutations to total tissue mutations, with patients stratified into highly concordant (⩾50%) and poorly concordant (<50%) groups. Results: The overall tissue–plasma concordance rate was 40.8%, with shared variants exhibiting identical abundance patterns across sample types and capturing the majority of functionally relevant mutations. Single-nucleotide variants in tissue showed a higher detection rate in plasma than structural variants. Individual concordance rates displayed significant inter-patient variability. Higher tissue tumor mutation burden (odds ratio (OR) 2.165, 95% confidence interval (CI) 1.183–3.965) and plasma ctDNA fraction (OR 1.433, 95% CI 1.063–1.933) were independently associated with high concordance rates. In advanced-stage patients, the poorly concordant group showed lower CA125 elimination rate constant K (KELIM) scores (median 0.7 vs 1.3; 15.0% vs 68.8% patients with score ⩾1), indicating reduced chemosensitivity. The poorly concordant group demonstrated a higher disease recurrence rate (40.0% vs 6.2%) and elevated early recurrence risk (12-month progression-free survival rate 82.0% vs 100.0%) compared with the highly concordant group. Conclusion: In the field of ovarian cancer, NGS of ctDNA showed moderate concordance with tissue-based sequencing in the pretreatment setting, influenced by both technical and biological factors. The tissue–plasma concordance may serve as a chemosensitivity and prognostic indicator.

  • Open Access

    Management and Predictors of Treatment Failure in Patients with Chemo-Resistant/Relapsed Gestational Trophoblastic Neoplasia with Lung Metastasis

    by Yujia Kong, Weidi Wang, Jinkai Lin, Xirun Wan, Fengzhi Feng, Tong Ren, Jun Zhao, Junjun Yang, Yang Xiang

    The aim of the study was to assess the effectiveness of a combined treatment modality of salvage chemotherapy and pulmonary resection in chemo-resistant/relapsed gestational trophoblastic neoplasia (GTN) with lung metastasis and identify predictors of treatment failure. Data of patients with chemo-resistant/relapsed GTN with lung metastasis who received salvage chemotherapy combined with pulmonary resection were retrospectively analyzed. Among 134 included patients, the number of preoperative chemotherapy regimens ranged from 2–8 (median, 3), and courses ranged from 4–37 (median, 14). Pulmonary lobectomies, segmentectomies, wedge resections, and lobectomies plus wedge resections were performed in 84, 5, 35, and 10 patients, respectively. After completion of treatment, 130 (97.0%) patients achieved complete remission. In the entire cohort, the 5-year overall survival (OS) rate was 87.6%. OS rates were similar between stage III and stage IV disease cohorts (89.4% vs. 75.0%, p = 0.137). Preoperative β-human chorionic gonadotropin (β-hCG) levels > 10 IU/L (p = 0.027) and number of preoperative chemotherapy regimens > 3 (p = 0.018) were predictors of treatment failure. The combined treatment modality of salvage chemotherapy and pulmonary resection is effective in patients with chemo-resistant/relapsed GTN with lung metastasis, improving their prognoses. Patients with preoperative serum β-hCG >10 IU/L and those with >3 chemotherapy regimens preoperatively may not benefit from this multidisciplinary treatment.


  • Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study

    by Yujia Kong, Junjun Yang, Fang Jiang, Jun Zhao, Tong Ren, Jie Li, Xiaoyu Wang, Fengzhi Feng, Xirun Wan, Yang Xiang


  • Open Access

    Management and prognosis of patients with brain metastasis from gestational trophoblastic neoplasia: a 24-year experience in Peking union medical college hospital

    by Changji Xiao, Junjun Yang, Jing Zhao, Tong Ren, Fengzhi Feng, Xirun Wan, Yang Xiang

    The optimal treatment for patients with brain metastasis from gestational trophoblastic neoplasia (GTN) has not been established. This study aims to investigate the clinical characteristics and the management of brain metastasis from GTN in relation to patients’ outcomes. We retrospectively investigated 109 GTN patients with brain metastasis treated at Peking Union Medical College Hospital from January 1990 to December 2013. Patients mainly received multiagent chemotherapy with florouracil or floxuridine, dactinomycin, etoposide, and vincristine (FAEV) combined with intrathecal methotrexate with or without surgery. In the 109 patients, sixty-two (56.1%) patients presented for primary therapy and 47 patients had failed chemotherapy elsewhere. Eight early demise patients who died before or during first cycle of chemotherapy were excluded from analysis. The median follow-up time was 47 months (range 9–180 months). The overall 5-year survival rate (OS) was 71.1%, while the OS rate for patients receiving primary chemotherapy in our hospital was 85.5%, and this fell to 51.9% in patients with failure multidrug chemotherapy elsewhere. Multivariate analysis demonstrated that International Federation of Gynecology and Obstetrics (FIGO) scores over 12 (Hazard ratio-HR 1.279, 95% CI 1.061-1.541, P = 0.010), failure of previous multidrug chemotherapy (HR 3.177, 95% CI 1.277-7.908, P = 0.013), and concurrent renal metastasis (HR 2.654, 95% CI 1.125-6.261, P = 0.026) were the risk factors of overall survival in patients with brain metastases from GTN. Patients with brain metastasis from GTN have favorable outcome by multidrug chemotherapy and adjuvant therapies. Nevertheless, the prognosis is poor if the patients had previous multidrug failure chemotherapy history, concomitant with renal metastasis, or FIGO score over 12. Initial treatment with FAEV combined with intrathecal methotrexate chemotherapy can bring bright prospect to patients with brain metastases from GTN.


    • 1 October 2007
      • Vol. 52  (10) , 941-4

    Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor.

    by Xirun Wan, Yang Xiang, Xiuyu Yang, Yu Wu, Ning Liu, Ling Chen, Ruofan Dong

    To evaluate the efficacy of the FAEV regimen (floxuridine, actinomycin D, etoposide, vincristine) in the treatment of high-risk, drug-resistant gestational trophoblastic tumor (GTT). From October 2001 to May 2004, 11 cases of high-risk, drug-resistant GTT were treated with the FAEV regimen. All cases were referred to Peking Union Medical College Hospital because of previous failure of chemotherapy. The patients' ages ranged from 21 to 60 (median, 32) years. The International Federation of Gynecologists and Obstetricians score was 7-13 (median, 9). All cases were followed for 15-42 months after FAEV treatment. Seven cases (63.6%, 7 of 11) were cured by the FAEV regimen. The median course number for serum human chorionic gonadotropin reaching a normal level was 3. Four cases (36%, 4 of 11) showed drug resistance to the FAEV regimen. The major side effect of FAEV regimen is myelosuppression. Granulocyte colony-stimulating factor support was needed after 98.4% (63 of 64) of the courses. For high-risk, drug-resistant GTT cases, FAEV regimen could be an effective treatment.